the question remains, though, did DNDN respond to the FDA prior to PDUFA with the necessary corrections to the issues outlined in the 483?
The PDUFA date was May 15 and the FDA kicked DNDN in the shins on May 8. If correcting the CMC issues was the issue, it is inconceivable the FDA would not have given Dendreon until May 15.
The approvable letter is about wanting 9902B survival data. The lawsuit goes nowhere even if it backed by the former most recommended poster per posts.
Bankers almost certainly sign the same confidentiality agreements that potential partners sign and the "books" are opened up to them. In theory, none of them are allowed to trade on this information as the same rules now apply to them as apply to anyone with "insider knowledge."